Related Experiment Video
Updated: Jan 7, 2026

The 4 Mountains Test: A Short Test of Spatial Memory with High Sensitivity for the Diagnosis of Pre-dementia Alzheimer's Disease
Published on: October 13, 2016
Divergent patterns of cognitive decline in preclinical Alzheimer's disease: implications for secondary prevention
Background:
Alzheimer's disease biomarkers in cognitively unimpaired older adults are associated with later cognitive and clinical decline, yet substantial heterogeneity in the timing and rate of decline remains insufficiently characterized. This study aims to identify subgroups of cognitive decline among biomarker-defined cognitively unimpaired adults and determine baseline predictors of heterogeneity in preclinical Alzheimer's disease progression.
Methods:
Longitudinal data was analyzed from the Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) Study, which enrolled amyloid-positive participants, and the parallel LEARN Study, which enrolled amyloid-negative individuals meeting all other A4 criteria. Participants completed baseline amyloid PET, plasma P-tau217, structural MRI, and serial cognitive assessments. Latent Class Mixed-Effects Models (LCMMs) were used to identify distinct cognitive trajectory classes. Associations between class membership and demographic, clinical, and biomarker characteristics were evaluated. The primary outcome was longitudinal change in the Preclinical Alzheimer Cognitive Composite (PACC).
Findings:
Three cognitive trajectory classes were identified: stable, slow decliners, and fast decliners. Higher plasma P-tau217, smaller hippocampal volume, and elevated tau PET were associated with greater odds of belonging to declining classes. Among amyloid-positive individuals, approximately 70% were classified as stable over the observed follow-up interval. These stable individuals likely contribute little to the power of preclincal Alzheimer's trials.
Interpretation:
Latent class modeling reveals marked heterogeneity in preclinical cognitive trajectories, even among individuals with biomarker evidence of Alzheimer pathology. The high proportion of stable individuals, though consistent with the long presymptomatic interval, has important implications for prevention trial design, particularly regarding inclusion criteria, outcome measures, and treatment effect assumptions. Identifying subgroups of decline may improve prognostic modeling and guide enrichment strategies for precision secondary prevention trials.
Funding:
US National Institutes of Health, Eli Lilly, Alzheimer's Association, Foundation for the National Institutes of Health, GHR Foundation, Davis Alzheimer Prevention Program, Yugilbar Foundation, Avid Radiopharmaceuticals, Cogstate, Albert Einstein College of Medicine, Foundation for Neurologic Diseases, and Epstein Family Foundation.
More Related Videos
Related Concept Videos
Cognitive Development During Adulthood
Cognitive Learning
E. C. Tolman's theory of purposive behavior emphasizes that much behavior is goal-directed. He argued that to understand behavior, we must look at the entire sequence of actions leading to a goal. For instance, high school students study hard, not just due to past reinforcement but also to achieve the goal of getting into a good college.
Tolman introduced the idea that behavior is influenced by...
Cognitivism
Previously dominated by behaviorism, which prioritized observable behaviors and largely ignored mental processes, psychology transformed in the 1950s. Cognitive psychologists argue that understanding how we think and process...
Language and Cognition
Higher Mental Functions of Brain: Learning and Memory
Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...

